Onconova Therapeutics Inc (Nasdaq:ONTX)
September 26th, 2018
Amidst falling markets Onconova Therapeutics Inc fell $0.24 Wednesday, a 2.99% drop, closing at $7.73. Onconova Therapeutics Inc bounced 61.42% between high and low. Despite the drop in value, trading volumes were solid at 3,086% of normal which can indicate investor opportunities.
ONTX was outperformed by the rest of the Healthcare sector which went up 0.20%.
The market sectors were mixed Wednesday with a majority of the sectors trending down. Communication Services saw the biggest increase of the day (0.35%), while Financials saw the biggest drop (1.27%). Information Technology has seen the biggest year-to-date gain at 19%. The biggest loss this year has been the Consumer Staples sector falling 5.60%.
Consumer Staples saw the biggest turnaround from its 5-day performance of -0.98%, as it went up 0.06%. Financials and Materials both saw turn arounds from their five day positive performance, Financials with a drop of 1.27%.
- Communication Services went up with a 0.35% change.
- Healthcare went up with a 0.20% change.
- Consumer Discretionary went up with a 0.19% change.
- Consumer Staples went up with a 0.06% change.
- Industrials went down with a -0.15% change.
- Information Technology went down with a -0.41% change.
- Energy went down with a -0.99% change.
- Materials went down with a -1.03% change.
- Utilities went down with a -1.04% change.
- Real Estate went down with a -1.15% change.
- Financials went down with a -1.27% change.
Onconova Therapeutics Inc Info
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.